Jean Bennett
Directeur/Membre du Conseil chez REGENXBIO INC.
Fortune : 48 341 $ au 30/04/2024
Postes actifs de Jean Bennett
Sociétés | Poste | Début | Fin |
---|---|---|---|
REGENXBIO INC. | Directeur/Membre du Conseil | 01/03/2021 | - |
Independent Dir/Board Member | 01/03/2021 | - | |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Directeur/Membre du Conseil | 01/02/2021 | - |
Fondateur | 01/02/2021 | - | |
Perelman School of Medicine | Corporate Officer/Principal | - | - |
Historique de carrière de Jean Bennett
Anciens postes connus de Jean Bennett
Sociétés | Poste | Début | Fin |
---|---|---|---|
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Fondateur | - | - |
SPARK THERAPEUTICS, INC. | Fondateur | - | - |
Gensight Biologics, Inc. | Fondateur | - | - |
Center For Advanced Retinal & Ocular Therapies | Directeur/Membre du Conseil | - | - |
Formation de Jean Bennett
Harvard University | Doctorate Degree |
Yale University | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 11 |
Opérationnelle
Founder | 4 |
Director/Board Member | 3 |
Doctorate Degree | 2 |
Sectorielle
Health Technology | 5 |
Consumer Services | 5 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
REGENXBIO INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Gensight Biologics, Inc. | |
Center For Advanced Retinal & Ocular Therapies | |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
- Bourse
- Insiders
- Jean Bennett
- Expérience